It's the most-searched peptide comparison out there, and most results jump straight to doses and "stacks." We're going to do it differently: what does the research actually say, and what can't it say yet?

The short version

BPC-157 and TB-500 are both peptides studied for tissue repair and recovery, mostly in animal models, and they're frequently discussed side by side. They're also both not FDA-approved, and the human evidence for either is limited. So "which is better" has no evidence-based winner, only different research angles.

How they differ on paper

BPC-157 is a synthetic peptide based on a sequence found in the gut; its research has explored localized tissue repair and gastrointestinal contexts, with proposed effects on new blood-vessel formation. TB-500 is a synthetic fragment related to a naturally occurring protein (thymosin beta-4), and its research has focused on cell migration and broader, more systemic tissue processes.

The internet frames it as a cage match. The research frames it as two early-stage compounds studied for overlapping but distinct questions, in mostly non-human models.

What the comparison can't tell you

  • Whether either reliably works in humans, large human trials are lacking for both.
  • Long-term safety, not well characterized for either.
  • What's actually in unregulated products, purity and identity vary widely.
No protocol here

We don't publish doses, schedules, or administration instructions. These compounds aren't FDA-approved, and turning early research into a self-use guide would misrepresent the evidence and the risk. Whether anything is appropriate is a decision for a licensed provider.

Bottom line

If you came for a dosing protocol or a definitive winner, we'll disappoint you, on purpose. Both are interesting research peptides, neither is proven or approved, and the right next step is a licensed provider. Read our BPC-157 and TB-500 deep dives for the details.